A Phase IIb randomized, placebo-controlled clinical trial testing the efficacy of PhytoSERM, a selective ERβ modulator comprised of three phytoestrogens: genistein, daidzein, and S-equol (Zhao et al., 2009), for support of bioenergetic and cognitive function in midlife women at risk for AD is underway. The gene discussed is ESR2; the disease is Alzheimer disease.